Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of SEP-363856 vs Quetiapine XR in Schizophrenia
2019-002259-40Phase 3Active
- Sponsor
- Sunovion
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ulotaront in schizophrenia (2 arms), sponsored by Sunovion. Primary endpoint: Overall adverse events. Started Mar 2022; status: active.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2019-002259-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002259-40.